Argentina’s health ministry said Russia’s COVID-19 vaccine Sputnik V is more effective at preventing coronavirus infections than its Chinese and Indian competitors, The Moscow Times reported.
According to the Telam news agency, Argentina has so far distributed the first doses of Sputnik V among 2.6 million recipients, China’s Sinopharm to among 1.2 million and India’s Covishield among more than half a million.
Argentina’s health ministry reported that 0.27% of Sputnik V recipients contracted COVID-19 two weeks after the first dose compared to 0.49% of Sinopharm and 0.46% of Covishield first-dose recipients.
"This is a surveillance evaluation," said Juan Manuel Castelli, the health ministry’s communicable disease control director. "The vaccine clearly decreases the potential occurrence of complications, hospitalizations and deaths but does not completely prevent the disease."
This week, Argentina’s research council published a report showing that 94% of Sputnik V first-dose recipients produced specific antibodies. The report, which involved 288 participants, said 100% of two-dose recipients had developed specific antibodies.
To read more NewsPoints articles, click here.